Microbot Medical Stock Net Income
| MBOT Stock | USD 1.67 0.04 2.34% |
Microbot Medical fundamentals help investors to digest information that contributes to Microbot Medical's financial success or failures. It also enables traders to predict the movement of Microbot Stock. The fundamental analysis module provides a way to measure Microbot Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Microbot Medical stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.7 M | -10.1 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Net Loss | -15.1 M | -15.9 M | |
| Net Loss | (0.95) | (1.00) | |
| Net Loss | (9.16) | (8.70) |
Microbot | Net Income |
Microbot Medical Company Net Income Analysis
Microbot Medical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Microbot Medical Net Income | (10.74 M) |
Most of Microbot Medical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Microbot Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Microbot Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Microbot Medical is extremely important. It helps to project a fair market value of Microbot Stock properly, considering its historical fundamentals such as Net Income. Since Microbot Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Microbot Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Microbot Medical's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Microbot Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Microbot Medical reported net income of (10.74 Million). This is 103.15% lower than that of the Health Care Equipment & Supplies sector and 110.78% lower than that of the Health Care industry. The net income for all United States stocks is 101.88% higher than that of the company.
Microbot Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Microbot Medical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Microbot Medical could also be used in its relative valuation, which is a method of valuing Microbot Medical by comparing valuation metrics of similar companies.Microbot Medical is currently under evaluation in net income category among its peers.
Microbot Medical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Microbot Medical from analyzing Microbot Medical's financial statements. These drivers represent accounts that assess Microbot Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Microbot Medical's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 49.0M | 53.3M | 21.9M | 16.7M | 19.2M | 18.3M | |
| Enterprise Value | 30.2M | 40.5M | 19.9M | 14.5M | 16.7M | 28.5M |
Microbot Medical Institutional Holders
Institutional Holdings refers to the ownership stake in Microbot Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Microbot Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Microbot Medical's value.| Shares | Two Sigma Securities, Llc | 2024-12-31 | 10.7 K | Stifel Financial Corp | 2024-12-31 | 10.3 K | Bb&t Corp. | 2024-12-31 | 10 K | Diamant Asset Management Inc | 2024-12-31 | 10 K | Wells Fargo & Co | 8.9 K | Beacon Capital Management, Llc | 2024-12-31 | 6 K | Bfsg, Llc | 2024-12-31 | 5.5 K | Tower Research Capital Llc | 2024-12-31 | 4.4 K | Sbi Securities Co Ltd | 2024-12-31 | 3 K | Vanguard Group Inc | 2024-12-31 | 459.5 K | Geode Capital Management, Llc | 2024-12-31 | 142.7 K |
Microbot Fundamentals
| Return On Equity | -2.01 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 55.17 M | ||||
| Shares Outstanding | 34.74 M | ||||
| Shares Owned By Insiders | 1.62 % | ||||
| Shares Owned By Institutions | 7.47 % | ||||
| Number Of Shares Shorted | 4.76 M | ||||
| Price To Earning | (3.42) X | ||||
| Price To Book | 15.60 X | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (10.74 M) | ||||
| Cash And Equivalents | 9.29 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 231 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.60 X | ||||
| Book Value Per Share | 0.23 X | ||||
| Cash Flow From Operations | (8.53 M) | ||||
| Short Ratio | 1.51 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.61 | ||||
| Market Capitalization | 59.41 M | ||||
| Total Asset | 8.33 M | ||||
| Retained Earnings | (79.5 M) | ||||
| Working Capital | 4.13 M | ||||
| Current Asset | 15.21 M | ||||
| Current Liabilities | 9.83 M | ||||
| Net Asset | 8.33 M |
About Microbot Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.